12:50 PM
 | 
Dec 05, 2018
 |  BC Extra  |  Company News

Tecentriq could be first front-line SCLC therapy approved in two decades

FDA accepted and granted Priority Review to an sBLA from Genentech Inc. for anti-PD-L1 mAb Tecentriq atezolizumab as first-line treatment of extensive-stage small cell lung cancer. Its PDUFA date is March 18, 2019.

Genentech CMO and Head of Global Product Development Sandra Horning said in a statement that Tecentriq...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >